WILEX AG, DE000A11QVV0

WILEX AG, DE000A11QVV0

24.04.2017 - 10:05:22

WILEX AG plans rights issue using authorised capital

Ad-hoc release - Insider information pursuant to Article 17 MAR

- Not for distribution, publication or transmission in the USA, Canada, Japan and Australia -

WILEX AG plans rights issue using authorised capital

Munich, Germany, 24 April 2017 - The Executive Management Board of WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today resolved, with the approval of the Supervisory Board, to increase the Company's share capital using authorized capital from EUR 12,927,564.00 by up to EUR 2,040,816.00 to up to EUR 14,968,380.00 by issuing up to 2,040,816 new no-par value shares with a notional value of EUR 1.00 each and full entitlement to dividends effective 1 December 2016 in return for cash contributions.

The new shares (ISIN DE000A2E4SX4 / WKN A2E / 4SX) will be offered exclusively to shareholders at a 19:3 ratio by means of an indirect subscription right by Baader Bank AG, Unterschleissheim. Shareholders will therefore be entitled to subscribe for 3 new shares for each 19 existing shares held. In order to ensure an even subscription ratio, one shareholder waived its subscription rights from 2,396 old shares.

The subscription period will begin on 26 April 2017 at 0:00 am CET and will end on 10 May 2017 at 02:00 pm CET. The subscription price is fixed at EUR 2.45. There will be no organized trading in subscription rights.

Any new shares not subscribed for as a result of the offer may be purchased by shareholders only - also at the subscription price - as part of an additional subscription for shares. Binding offers for such additional subscriptions must be submitted within the subscription period.

The main shareholder, dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany, has agreed to exercise its subscription rights and take over new shares not subscribed as part of the offer to exercise subscription and additional subscription rights.

WILEX AG plans to use the expected gross proceeds from the rights issue of EUR 4,999,999.20 million mainly to finance the preclinical development of its proprietary ATAC candidate HDP-101 and to establish the GMP manufacturing process for Antibody Targeted Amanitin Conjugates (ATACs).

The new shares (ISIN DE000A2E4SX4 / WKN A2E/ 4SX) are to be admitted to trading on the regulated market of the Frankfurt Stock Exchange (Prime Standard) without the publication of an offering prospectus and are expected to begin trading on 15 May 2017.

For further details on the rights issue, please see the subscription offer expected to be published in the Federal Gazette (www.bundesanzeiger.de) on 25 April 2017 and on the website of WILEX AG (www.wilex.com).

Important notes

This ad hoc release does not constitute either an offer to sell or an invitation to buy securities. In particular, this document does not constitute an offer to sell securities or a solicitation of an offer to buy securities in the United States of America. The shares of WILEX AG (the "Shares") may not be offered or sold in the United States of America or to or for the account or benefit of "U.S. persons" (as defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act")), unless they have been registered or are exempt from registration under the Securities Act. The Shares have not been and will not be registered under the Securities Act. There will be no public offer of Shares in the United States of America.

+++ End of the Ad Hoc-Release +++

About WILEX WILEX AG is a biopharmaceutical company based in Munich, Germany, that serves as a parent and holding company. The Company's research and development work is conducted by its subsidiary Heidelberg Pharma GmbH in Ladenburg. Heidelberg Pharma is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the company's own therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. WILEX's clinical assets MESUPRON(R) and REDECTANE(R) have been partnered, while RENCAREX(R) is available for out-licensing and further development. WILEX is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at http://www.wilex.com/.

Contact

WILEX AG Sylvia Wimmer Corporate Communications Tel.: +49 (0)89-41 31 38-29 Email: investors[at]wilex.com Grillparzerstr. 10, 81675 Munich, Germany IR/PR supportMC Services AG Katja Arnold (CIRO) Managing Director & Partner Tel.: +49-89-210 228-40 Email: katja.arnold[at]mc-services.eu      

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward- looking statements to reflect future events or developments.

24-Apr-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English

Company: WILEX AG Grillparzerstr. 18 81675 München

Germany Phone: +49 (0)89 41 31 38 - 0 Fax: +49 (0)89 41 31 38 - 99 E-mail: info@wilex.com Internet: www.wilex.com ISIN: DE000A11QVV0 WKN: A11QVV Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange   End of Announcement DGAP News Service

566497  24-Apr-2017 CET/CEST

@ dgap.de